Check out the blog I wrote back in January. The picks, including InMed, are still good going forward. The biggest question mark is Omni, which did a reverse merger last year and has had some problems auditing 40 years of financials for their 10-K and announcing their business plan. However the risk/reward is huge as they are significantly undervalued right now.
News 
Market Data 
Discover 
